New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
07:33 EDTCELGCelgene announces results from long-term Phase III OTEZLA trial
Celgene International SÓrl, a wholly-owned subsidiary of Celgene Corporation, announced results from a long-term phase III trial of OTEZLA, the companyĺs oral, selective inhibitor of phosphodiesterase 4, in psoriatic arthritis patients who have not had prior treatment with systemic or biologic disease-modifying antirheumatic drugs. The data were presented at the European League Against Rheumatism Annual Congress in Paris, France. Results demonstrated that treatment with OTEZLA monotherapy in patients with pre-existing enthesitis or dactylitis, two key manifestations of psoriatic arthritis, resulted in long-term improvements. Results were sustained over 52 weeks in patients initially randomized to OTEZLA monotherapy and completing 52 weeks of the study. At week 52, median Maastricht Ankylosing Spondylitis Enthesitis Scoredecreased by 75.0 percent and 45.9 percent of patients receiving OTEZLA 30 mg BID achieved a score of 0, indicating no pain at any of the enthesitis sites assessed. OTEZLA 30 mg BID also resulted in a median 100 percent decrease in dactylitis count. A dactylitis count of 0, indicating no signs of dactylitis, was achieved in 68.8 percent of patients.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
11:00 EDTCELGCelgene to hold an analyst and investor event
Subscribe for More Information
07:06 EDTCELGAmerican Society of Clinical Oncology to hold annual meeting
Subscribe for More Information
May 26, 2015
20:50 EDTCELGBernstein to hold a conference
Subscribe for More Information
07:39 EDTCELGCelgene management to meet with SunTrust
Group dinner to be held in New York on May 27 hosted by SunTrust.
May 21, 2015
08:08 EDTCELGAgios Pharmaceuticals to present data at 20th Congress of EHA
Subscribe for More Information
May 19, 2015
08:17 EDTCELGCelgene says patients experienced clinical remission in Phase II GED-0301 trial
Subscribe for More Information
May 18, 2015
08:44 EDTCELGCelgene data positive, says SunTrust
SunTrust believes that data presented for Celgene's GED-0301 in Crohn's indicated that the drug is effective irrespective of baseline disease severity and CRP levels.Consequently, the firm thinks the data addressed questions raised in an NEJM editorial about the drug. It keeps a $141 price target and Buy rating on the shares.
07:31 EDTCELGCelgene, Acceleron granted fast track designations for luspatercept
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use